1. Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo
- Author
-
Kevin N. Dalby, Matthew Harger, Kenneth Y. Tsai, Pengyu Ren, Rachel M. Sammons, Tamer S. Kaoud, Clint D.J. Tavares, Jacey R. Pridgen, Ramakrishna Edupuganti, Mohamed F. Radwan, Diana Zamora-Olivares, Nancy D. Ebelt, Sabrina X. Van Ravenstein, Eric V. Anslyn, Mangalika Warthaka, Jihyun Park, Micael Cano, William H. Johnson, Ranajeet Ghose, and Andrea Piserchio
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Cell cycle checkpoint ,General Physics and Astronomy ,Apoptosis ,medicine.disease_cause ,Dioxanes ,0302 clinical medicine ,lcsh:Science ,Melanoma ,Mitogen-Activated Protein Kinase 1 ,Mutation ,Multidisciplinary ,Molecular medicine ,biology ,Chemistry ,MEK inhibitor ,Small molecule ,3. Good health ,Cell biology ,030220 oncology & carcinogenesis ,Protein Binding ,MAP Kinase Signaling System ,Science ,Mice, Nude ,Kinases ,Drug development ,Mechanism of action ,Molecular Dynamics Simulation ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Cysteine ,Protein Kinase Inhibitors ,Binding Sites ,HEK 293 cells ,Active site ,General Chemistry ,Xenograft Model Antitumor Assays ,Thiazoles ,HEK293 Cells ,030104 developmental biology ,biology.protein ,lcsh:Q - Abstract
Recently, the targeting of ERK with ATP-competitive inhibitors has emerged as a potential clinical strategy to overcome acquired resistance to BRAF and MEK inhibitor combination therapies. In this study, we investigate an alternative strategy of targeting the D-recruitment site (DRS) of ERK. The DRS is a conserved region that lies distal to the active site and mediates ERK–protein interactions. We demonstrate that the small molecule BI-78D3 binds to the DRS of ERK2 and forms a covalent adduct with a conserved cysteine residue (C159) within the pocket and disrupts signaling in vivo. BI-78D3 does not covalently modify p38MAPK, JNK or ERK5. BI-78D3 promotes apoptosis in BRAF inhibitor-naive and resistant melanoma cells containing a BRAF V600E mutation. These studies provide the basis for designing modulators of protein–protein interactions involving ERK, with the potential to impact ERK signaling dynamics and to induce cell cycle arrest and apoptosis in ERK-dependent cancers., The ERK signalling pathway is activated in many cancers, however ERK1 and ERK2 are difficult to target pharmacologically. Here, the authors identify a small molecule inhibitor that binds covalently to the D-recruitment site of ERK and induces cell death and reduces tumour growth in mice.
- Published
- 2019